摘要
目的:观察依达拉奉对急性脑梗死患者血清IL-17、IL-6和TNF-α的影响。方法:选择发病24 h内的急性脑梗死患者63例,随机分为依达拉奉组和对照组,对照组31例按急性脑梗死常规方法治疗2周,依达拉奉组32例在常规治疗基础上加用依达拉奉治疗2周,治疗前、治疗后7 d、14 d检测患者血清IL-17、IL-6和TNF-α。结果:两组患者治疗前及治疗7 d IL-17、IL-6、TNF-α水平无统计学差异,但治疗14 d依达拉奉组各项指标均低于对照组,差异有统计学意义。两组患者治疗7 d和14 d IL-17、IL-6、TNF-α水平均低于治疗前,差异有统计学意义。结论:依达拉奉能显著降低急性脑梗死患者血清炎症因子IL-17、IL-6和TNF-α的水平,这可能是其治疗脑梗死的机制之一。
Objective：To study effects of edaravone on the levels of serum interleukin-17 （IL-17）, IL-6, tumor necrosis factor-α （TNF-α） in patients with acute cerebral infarction. Methods： 63 patients of cerebral infarction were randomly divided and assigned to edaravone group and control group. 31 patients in control group were treated by routine therapy of acute cerebral infarction two weeks. Another 32 patients in edaravone group were treated with routine therapy and edaravune for two weeks. The levels of serum IL-17, IL-6, and TNF-α were measured by enzyme-linked immunosorbent assay before treatment and after treatment 7d and 14d. Results： Although there were no difference before treatment and after treatment 7d,the levels of serum IL-17,IL-6,and TNF-α were found to be sharply decreased in edaravone group compared with the control group after treatment 14d. The levels of serum IL-17,IL-6, and TNF-α in two groups were lower significantly after treatment 7d and 14d than before treatment. Conclusions： Edaravone can decrease the levels of serum IL-17 ,IL-6, and TNF-α ,which probably reduce the injury of ischemic brain and improve therapeutic efficacy.
出处
《赣南医学院学报》
2009年第3期399-401,共3页
JOURNAL OF GANNAN MEDICAL UNIVERSITY
